$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000143774919021599 Filed on November 05, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$2.560M	$2.410M	$2.020M
YoY Change	26.11%	19.31%	-2.46%
Cost Of Revenue	$1.640M	$1.563M	$1.477M
YoY Change	11.56%	5.82%	-54.89%
Gross Profit	$930.0K	$847.0K	$543.0K
YoY Change	66.07%	55.99%	-145.14%
Gross Profit Margin	36.33%	35.15%	26.88%
Selling, General & Admin	$4.370M	$4.091M	$4.499M
YoY Change	-11.9%	-9.07%	-8.71%
% of Gross Profit	469.89%	483.0%	828.55%
Research & Development	$1.570M	$1.371M	$1.404M
YoY Change	-5.99%	-2.35%	-39.53%
% of Gross Profit	168.82%	161.87%	258.56%
Depreciation & Amortization	$240.0K	$220.0K	$220.0K
YoY Change	-55.56%	0.0%	-29.03%
% of Gross Profit	25.81%	25.97%	40.52%
Operating Expenses	$5.930M	$5.462M	$5.903M
YoY Change	-10.56%	-7.47%	-23.0%
Operating Profit	-$5.000M	-$4.615M	-$5.360M
YoY Change	-17.63%	-13.9%	-39.56%
Interest Expense	-$340.0K	$377.0K	$324.0K
YoY Change	30.77%	16.36%	-79.74%
% of Operating Profit
Other Income/Expense, Net	$230.0K	$299.0K	$242.0K
YoY Change	-4.17%	23.55%
Pretax Income	-$5.120M	-$4.620M	-$5.390M
YoY Change	-15.93%	-14.29%	-48.37%
Income Tax
% Of Pretax Income
Net Earnings	-$5.120M	-$4.623M	-$5.388M
YoY Change	-15.93%	-14.2%	-48.41%
Net Earnings / Revenue	-200.0%	-191.83%	-266.73%
Basic Earnings Per Share
Diluted Earnings Per Share	-$492.8K	-$584.8K	-$4.812M
COMMON SHARES
Basic Shares Outstanding	10.35M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.94M	$14.46M	$10.01M
YoY Change	-33.33%	44.46%	-1.57%
Cash & Equivalents	$10.94M	$14.46M	$10.01M
Short-Term Investments
Other Short-Term Assets	$310.0K	$490.0K	$730.0K
YoY Change	-51.56%	-32.88%	-17.05%
Inventory	$3.912M	$4.112M	$3.450M
Prepaid Expenses
Receivables	$1.458M	$1.301M	$1.460M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.62M	$20.36M	$15.65M
YoY Change	-23.11%	30.12%	-9.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.661M	$1.873M	$2.065M
YoY Change	-20.07%	-9.3%	-40.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$684.0K	$579.0K	$584.0K
YoY Change		-0.86%	165.45%
Total Long-Term Assets	$7.201M	$7.644M	$2.649M
YoY Change	246.54%	188.56%	-28.02%
TOTAL ASSETS
Total Short-Term Assets	$16.62M	$20.36M	$15.65M
Total Long-Term Assets	$7.201M	$7.644M	$2.649M
Total Assets	$23.83M	$28.01M	$18.30M
YoY Change	0.53%	53.06%	-12.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$663.0K	$919.0K	$2.158M
YoY Change	-42.25%	-57.41%	156.9%
Accrued Expenses	$654.0K	$681.0K	$577.0K
YoY Change	-54.87%	18.02%	-83.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.970M	$8.580M	$8.150M
YoY Change	19.76%	5.28%	-81.09%
Total Short-Term Liabilities	$12.79M	$14.91M	$13.95M
YoY Change	-9.93%	6.87%	-70.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.000K	$9.000K	$187.0K
YoY Change	-82.93%	-95.19%	3.89%
Total Long-Term Liabilities	$7.000K	$9.000K	$187.0K
YoY Change	-82.93%	-95.19%	3.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.79M	$14.91M	$13.95M
Total Long-Term Liabilities	$7.000K	$9.000K	$187.0K
Total Liabilities	$16.93M	$19.25M	$14.14M
YoY Change	18.9%	36.2%	-70.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$348.3M	-$343.2M	-$322.8M
YoY Change	5.91%	6.33%
Common Stock	$355.2M	$352.0M	$327.0M
YoY Change	4.99%	7.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.895M	$8.754M	$4.162M
YoY Change
Total Liabilities & Shareholders Equity	$23.83M	$28.01M	$18.30M
YoY Change	0.53%	53.06%	-12.74%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$5.120M	-$4.623M	-$5.388M
YoY Change	-15.93%	-14.2%	-48.41%
Depreciation, Depletion And Amortization	$240.0K	$220.0K	$220.0K
YoY Change	-55.56%	0.0%	-29.03%
Cash From Operating Activities	-$3.520M	-$4.120M	-$3.090M
YoY Change	-12.66%	33.33%	-55.79%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$280.0K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$30.00K
YoY Change		-100.0%
Cash From Investing Activities	$0.00	$0.00	-$250.0K
YoY Change	-100.0%	-100.0%	-2600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	3.830M	3.210M
YoY Change	-99.9%	19.31%	0.63%
NET CHANGE
Cash From Operating Activities	-3.520M	-4.120M	-3.090M
Cash From Investing Activities	0.000	0.000	-250.0K
Cash From Financing Activities	10.00K	3.830M	3.210M
Net Change In Cash	-3.510M	-290.0K	-130.0K
YoY Change	-154.84%	123.08%	-96.57%
FREE CASH FLOW
Cash From Operating Activities	-$3.520M	-$4.120M	-$3.090M
Capital Expenditures	$0.00	$0.00	-$280.0K
Free Cash Flow	-$3.520M	-$4.120M	-$2.810M
YoY Change	-20.18%	46.62%	-59.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2685000
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2082000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	5000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	3500000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Prepayment Multiplier For Revenue Shortfall DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall	2
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Avinger Inc
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Central Index Key EntityCentralIndexKey	0001506928
	dei	Trading Symbol TradingSymbol	avgr
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Eighth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueEighthYear	25000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Seventh Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSeventhYear	20000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Sixth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSixthYear	15000000
CY2015Q3	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.07
CY2018Q1	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.15
CY2015Q3	avgr	Debt Instrument Financing Fee Percentage DebtInstrumentFinancingFeePercentage	0.015
CY2015Q3	avgr	Debt Instrument Redemption Annual Decline In Prepayment Premium Percentage DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage	0.01
CY2015Q3	avgr	Debt Instrument Redemption Initial Prepayment Premium Percentage DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage	0.05
CY2015Q3	avgr	Debt Instrument Redemption Prepayment Premium Percentage After Fifth Year DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear	0
	avgr	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-984000
	avgr	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability
	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-32000
	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-115000
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	1146000
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	5330000
CY2019Q3	avgr	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	225000
	avgr	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	444000
	avgr	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	104000
	avgr	Payment Of Accrued Interest PaymentOfAccruedInterest
	avgr	Payment Of Accrued Interest PaymentOfAccruedInterest	60000
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5216000
CY2019Q3	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
CY2018Q3	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	15534000
CY2019Q3	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	3800000
CY2018Q4	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	10200000
CY2018Q3	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	3
CY2018Q1	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	15500000
	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	8000000
	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	3811000
	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	3539000
	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	54000
	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	128000
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	358000
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent
	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7993000
	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	581000
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	380000
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	103000
	avgr	Warranty Period WarrantyPeriod	P1Y
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	919000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1148000
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1301000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1154000
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	681000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1449000
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	351958000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	338342000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	895000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	836000
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2685000
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2082000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	523000
	dei	Document Type DocumentType	10-Q
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10351959
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	768000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1532000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2027000
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	523000
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	768000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1532000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2028000
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	185000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	260000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	129000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	87000
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3181759
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1964996
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3715785
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1523421
CY2019Q3	us-gaap	Assets Assets	28007000
CY2018Q4	us-gaap	Assets Assets	23699000
CY2019Q3	us-gaap	Assets Current AssetsCurrent	20363000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21621000
CY2019Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14461000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16410000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5389000
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10008000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1949000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4619000
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1797900
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2753999
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4757539
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	1477000
	us-gaap	Cost Of Revenue CostOfRevenue	4629000
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10342179
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3492200
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	10000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q3	us-gaap	Cost Of Revenue CostOfRevenue	1563000
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10342179
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3492200
	us-gaap	Cost Of Revenue CostOfRevenue	5061000
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	38000000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	654000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	735000
CY2019Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	2685000
CY2018Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	2918000
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.56
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.75
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-43
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1189000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1197000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2019Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2018Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2019Q3	us-gaap	Gross Profit GrossProfit	847000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	28000
CY2018Q3	us-gaap	Gross Profit GrossProfit	543000
	us-gaap	Gross Profit GrossProfit	1940000
	us-gaap	Gross Profit GrossProfit	826000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1149000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-776000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	59000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-229000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	297000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	147000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	378000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-768000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2618000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-8000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	123000
CY2019Q3	us-gaap	Interest Expense InterestExpense	377000
CY2018Q3	us-gaap	Interest Expense InterestExpense	324000
	us-gaap	Interest Expense InterestExpense	1091000
	us-gaap	Interest Expense InterestExpense	5358000
	us-gaap	Interest Paid Net InterestPaidNet
	us-gaap	Interest Paid Net InterestPaidNet	60000
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1670000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1162000
CY2019Q3	us-gaap	Inventory Net InventoryNet	4112000
CY2018Q4	us-gaap	Inventory Net InventoryNet	3422000
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1898000
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2102000
CY2019Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	544000
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000
	us-gaap	Inventory Write Down InventoryWriteDown	80000
	us-gaap	Inventory Write Down InventoryWriteDown	630000
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	70000
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	54000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	242000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	137000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	106000
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6128000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1138000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1203000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1162000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1123000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1085000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	418000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	937000
CY2019Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2019Q3	us-gaap	Liabilities Liabilities	19253000
CY2018Q4	us-gaap	Liabilities Liabilities	14239000
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28007000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23699000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19439000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-383000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13737000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14437000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4623000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-5388000
	us-gaap	Net Income Loss NetIncomeLoss	-14329000
	us-gaap	Net Income Loss NetIncomeLoss	-21468000
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14907000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14198000
CY2015Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Organization, Nature of Business</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007.</div> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “OCT”) </div>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company’s current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot MVRX, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the U.S. Food and Drug Administration (“FDA”) for commercialization of Pantheris, the Company’s image-guided atherectomy system, designed to allow physicians to precisely remove arterial plaque in PAD patients. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018, </div>the Company also received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(K) clearance from the FDA for its next-generation of Pantheris. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2019, </div>the Company further received FDA clearance for Pantheris SV, a lower profile Pantheris, and commenced sales in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2019. </div>The Company has sales in the U.S. and select international markets. The Company is located in Redwood City, California.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.4pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Liquidity Matters</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>) </div>requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date of the issuance of these financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019, </div>the Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$343.2</div> million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14.5</div> million at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> Even though we received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.8</div> million from the sales of our common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2019 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million from the sale of our Series C Preferred Stock and common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million from the sale of common stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2018 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million from the sale of our Series B preferred stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, and proceeds from issuance of common stock upon the exercise of warrants in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.0</div> million, the Company will need to raise additional funds through future equity or debt financings within the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>subsequently require additional fundraising. The Company can provide <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> create substantial dilution for our existing stockholders. Given the recent decline in the Company’s stock price, any financing that we undertake in the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months could cause substantial dilution to our existing stockholders, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have to significantly reduce its operations or delay, scale back or discontinue the development of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of its products. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>has been classified as current in these financial statements. CRG has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> invoked the material adverse change clause.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Public Offerings</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,979</div> shares of Series B preferred stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,797,900</div> shares of common stock. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million after underwriting discounts, commissions, legal and accounting fees. The Series B preferred stock has a liquidation preference of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, full ratchet price based anti-dilution protection, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> stated maturity, and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> pay regularly stated dividends or interest. Each share of Series B preferred stock is accompanied by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> warrant that expires on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> warrant that expires on the earlier of (i) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance or (ii) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60th</div> calendar day following the receipt and announcement of FDA clearance of our Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> shares of common stock; provided, however, if at any time during such <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> year anniversary of the initial exercise date. FDA clearance of Pantheris SV was received in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2019, </div>triggering this <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period. During the entire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period following clearance, the volume weighted average price was less than the then effective exercise price. As such, all Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> warrants are currently deemed to expire on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance. In addition, pursuant to the Series A Purchase Agreement, we issued to CRG <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,800</div> shares of Series A preferred stock at the closing of the Series B Offering. The Series A preferred stock was issued in exchange for the conversion of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38.0</div> million of the outstanding principal amount of their senior secured term loan (plus the back-end fee and prepayment premium applicable thereto), totaling approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$41.8</div> million. The Series A Preferred Stock is initially convertible into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,090,000</div> shares of common stock subject to certain limitations contained in the Series A Purchase Agreement.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we entered into a securities purchase agreement with certain investors pursuant to which we agreed to sell and issue, in a registered direct offering, an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,618</div> shares of our common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.425</div> per share. In a concurrent private placement, or the Private Placement, we agreed to issue to these investors warrants exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of our common stock for each <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> shares purchased in the registered direct offering, which equals an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,309</div> shares of common stock. The closing of such registered direct offering and the concurrent Private Placement occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> in connection with which we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million after deducting placement agent fees and other expenses payable by us. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.80</div> per share of our common stock and expire on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 1, 2018, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">728,500</div><div style="display: inline; text-decoration: underline;"> </div>shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,586</div> shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 26, 2019, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,813,559</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.18</div> per share. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.8</div> million after underwriting discounts, commissions, legal and accounting fees and the conversion price of the outstanding shares of Series B preferred stock, issued in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.18</div> per share as a result.</div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11858000
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5518000
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6224000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17014000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28766000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	5462000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	5903000
	us-gaap	Operating Expenses OperatingExpenses	16288000
	us-gaap	Operating Expenses OperatingExpenses	17783000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4615000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5360000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14348000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16957000
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000
CY2018Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	481000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5192000
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	855000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4337000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6000000
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5192000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	579000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41000
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	299000
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	242000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	868000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	710000
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	155000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	411000
CY2019Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	895000
CY2018Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	836000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2685000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2082000
CY2019Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	46535000
CY2018Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	44718000
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	44923
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	45671
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	44923
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	45671
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	489000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	635000
CY2019Q3	us-gaap	Prepaid Rent PrepaidRent	358000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	28000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7993000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	581000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	272000
CY2019Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	214000
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	70000
	us-gaap	Profit Loss ProfitLoss	-14329000
	us-gaap	Profit Loss ProfitLoss	-21468000
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1873000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2078000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	45000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1371000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1404000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4120000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4340000
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-343214000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328885000
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2410000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2020000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6569000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5887000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4680000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	8578000
CY2018Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7486000
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4091000
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4499000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12168000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13443000
	us-gaap	Share Based Compensation ShareBasedCompensation	1532000
	us-gaap	Share Based Compensation ShareBasedCompensation	2028000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7181000
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1300.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	433000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	105000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7954000
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7416000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1707.30
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1316.32
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7416000
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1316.32
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3015.01
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1929.52
CY2019Q3	us-gaap	Share Price SharePrice	0.83
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y18D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y251D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y18D
	us-gaap	Stock Issued1 StockIssued1	2918000
	us-gaap	Stock Issued1 StockIssued1
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	18000
CY2018Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	54000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000
CY2018Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	106000
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3811000
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3021000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3811000
CY2019Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	337000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	9920000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	8754000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	6592000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	4162000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	9460000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-35690000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div></div></div></div></div></div></div></div>
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7900000
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1119000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6189000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	669000
CY2018	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0

Files In Submission

Name	View Source	Status
0001437749-19-021599-index-headers.html	Edgar Link	pending
0001437749-19-021599-index.html	Edgar Link	pending
0001437749-19-021599.txt	Edgar Link	pending
0001437749-19-021599-xbrl.zip	Edgar Link	pending
avgr-20190930.xml	Edgar Link	completed
avgr-20190930.xsd	Edgar Link	pending
avgr-20190930_cal.xml	Edgar Link	unprocessable
avgr-20190930_def.xml	Edgar Link	unprocessable
avgr-20190930_lab.xml	Edgar Link	unprocessable
avgr-20190930_pre.xml	Edgar Link	unprocessable
avgr20190930_10q.htm	Edgar Link	pending
ex_160318.htm	Edgar Link	pending
ex_160319.htm	Edgar Link	pending
ex_160320.htm	Edgar Link	pending
ex_161115.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2019 Q4 Form 10-Q Financial Statement

#000143774919021599 Filed on November 05, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2019 Q4 Form 10-Q Financial Statement

#000143774919021599 Filed on November 05, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr